Study summary

Adding immunotherapy around surgery improved survival in stomach cancer

MATTERHORN trial · 948 people, phase 3 · Published June 2025, New England Journal of Medicine; FDA approved November 2025; final survival in The Lancet, 2026

69%alive at 3 years with durvalumab, vs 62%

What was tested

Durvalumab added to FLOT chemotherapy before and after surgery, then durvalumab alone, against FLOT with placebo, for stomach and gastroesophageal junction cancer that can be removed.

What they found

Risk of relapse, progression or death was 29% lower (hazard ratio 0.71).
3-year survival was 69% vs 62% in the final analysis.

What it means

The first immunotherapy approved around surgery for stomach cancer.

N Engl J Med, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.